The study, led by a multidisciplinary team spanning surgery, radiology, and radiation oncology at Vancouver General Hospital, examined every adult patient who underwent liver transplantation for hepatocellular carcinoma between 2015 and 2023 and who had received either yttrium-90 transarterial radioembolization (TARE) or stereotactic body radiation therapy (SBRT) as their final radiation treatment before surgery. Fifty-six patients met the criteria: twenty-three had been treated with TARE and thirty-three with SBRT. Unlike many prospective trials that enroll only treatment-naïve patients with tightly controlled tumor characteristics, this cohort reflected the reality of modern transplant medicine, where patients often arrive having already been through multiple rounds of ablation, chemoembolization, or other locoregional therapies before radiation is even considered.

The choice between the two modalities was not random. A multidisciplinary Liver Tumor Board assigned each patient to a treatment based on tumor burden, anatomy, liver function, and prior treatment history. TARE, which delivers microscopic radioactive yttrium-90 spheres directly into the arterial supply of the tumor, was preferentially selected for patients with higher baseline tumor burden, larger maximum tumor diameter (3.8 versus 3.2 centimeters), and greater total tumor volume (29.6 versus 17.9 cubic centimeters). SBRT, which delivers precisely targeted high-dose radiation beams from outside the body in just a few fractions, was more frequently deployed as a salvage option after prior multimodal therapy—used in 79 percent of the SBRT group versus 35 percent of the TARE group—and was favored for lesions in anatomically challenging positions where other approaches were considered unsuitable.

The technical execution of SBRT in this study reflects the sophistication of modern radiation delivery. The gross tumor volume was defined as arterial-enhancing lesions with delayed washout on co-registered diagnostic imaging, with a 5-millimeter clinical target volume margin confined to the liver parenchyma. Motion management—critical in an organ that moves with every breath—was achieved through dynamic tumor tracking, respiratory gating, or internal target volume strategies tailored to each patient. Daily cone-beam CT guidance was used for cases that could not be gated or tracked. Planning strictly prioritized organ-at-risk constraints over target volume coverage, reflecting the delicate balance between eradicating cancer and preserving enough functional liver tissue to keep the patient transplantable. The median prescribed dose was 45 Gy in three to five fractions, corresponding to a median biologically effective dose of 112.5 Gy.

On post-treatment imaging, non-viable disease was reported in 52.2 percent of TARE-treated lesions and 57.6 percent of SBRT-treated lesions, while viable disease persisted in 30.4 percent and 15.2 percent respectively—a difference that did not reach statistical significance. Both approaches were well tolerated. Median MELD scores, a measure of liver disease severity used to prioritize transplant allocation, were 8 in both groups before treatment and changed by only one point afterward, indicating that neither modality imposed meaningful additional liver damage. There was one suspected case of radiation-induced liver disease following SBRT, presenting as hepatic decompensation. The median interval from final radiation to transplantation was comparable between groups—337 days for SBRT and 360 days for TARE—and post-transplant outcomes, including surgical complications and length of hospital stay, were similarly unremarkable across both pathways.

But the most striking findings emerged when the researchers compared what the imaging said before transplant with what the pathologist found when the explanted liver was examined under the microscope. Pathologic complete response—the gold standard for confirming that every cancer cell has been eradicated—was observed in 36.4 percent of SBRT-treated lesions and 21.7 percent of TARE-treated lesions. While the SBRT figure was numerically higher, the authors caution that this likely reflects a cumulative treatment effect from prior therapies and a lower baseline tumor burden in that group rather than true superiority of one modality over the other. More concerning was the degree of radiographic-pathologic discordance: nearly identical between the two groups at roughly 40 percent. Among lesions that imaging had classified as non-viable, only 58 percent actually demonstrated complete necrosis on explant pathology.

This discordance has profound implications. Cross-sectional imaging in the post-radiation setting is fundamentally limited by treatment-induced fibrosis and inflammatory changes that can mask residual viable tumor. The LI-RADS Treatment Response algorithm, the standard framework for assessing post-treatment imaging in liver cancer, showed an overall predictive odds ratio of 4.22 for identifying complete necrosis, but neither the SBRT nor the TARE subgroup individually demonstrated a statistically significant association between radiographic classification and pathologic viability. Similarly, there was no meaningful correlation between radiographic and pathologic total tumor volume across the cohort, although the SBRT group did show a stronger Pearson correlation (r = 0.76) than the TARE group (r = −0.07), likely a reflection of the lower overall tumor burden in that cohort rather than a true difference in imaging accuracy.

Alpha-fetoprotein, the most widely used serum biomarker for hepatocellular carcinoma, fared no better as a predictor of pathologic complete response. In multivariable analysis adjusting for baseline AFP, tumor burden, and Milan status, the AFP log-ratio was not associated with pathologic complete response (odds ratio 1.13, p = 0.81). This reinforces growing concerns that AFP kinetics may be an imperfect surrogate for tumor eradication in the post-radiation setting, where the biology of residual disease may not track with conventional biomarker behavior. The authors suggest that emerging tools such as circulating tumor DNA and radiomics—the extraction of quantitative features from medical images—might eventually provide more granular data to improve prediction of tumor burden and recurrence before and after transplantation.

Despite the limitations of pre-transplant assessment, post-transplant outcomes were favorable across both groups over a comparable median follow-up of approximately three years. Recurrence-free survival at one and three years was 91.3 percent and 77.1 percent for TARE and 93.9 percent and 76.7 percent for SBRT respectively. In an adjusted Cox model, treatment modality was not associated with post-transplant recurrence (hazard ratio 1.49, p = 0.56). Overall survival at one and three years was similarly high with no significant differences between groups. These figures suggest that, regardless of which radiation modality is chosen as the final bridging treatment, patients who make it to transplantation can expect excellent long-term outcomes.

The study’s real-world per-lesion pathologic complete response rates sit below the figures reported in prospective trial data—for SBRT, the 36.4 percent rate is lower than the 58.3 percent reported in trials that exclusively evaluated treatment-naïve candidates, and for TARE, the 21.7 percent rate aligns with national registry data reporting an overall rate of 33.6 percent with center-level variation ranging from 0 to 50 percent. These differences likely reflect variations in patient selection, baseline tumor burden, prior treatment exposure, and definitions of pathologic response. The authors acknowledge the limitations of their retrospective design, modest sample size, and inherent treatment selection bias, as well as the absence of waitlist dropout data that would allow an intention-to-treat analysis. Nevertheless, the central message is clear: both TARE and SBRT are safe and feasible bridging strategies within contemporary transplant pathways for hepatocellular carcinoma, but clinicians must resist the temptation to overinterpret post-radiation imaging, because what the scan shows and what the pathologist finds are often two very different things.

Subject of Research: Bridging radiation therapies for hepatocellular carcinoma before liver transplantation

Article Title: Stereotactic body radiation therapy and radioembolization as bridging strategies to liver transplantation: a retrospective real-world analysis

Article References: Colucci, N., Webb, M. A., Khalid, M. U., Giannou, A. D., Yang, Y., Yan, T. D., Ma, L. I. J., Dhatt, R., Chartier-Plante, S., Kim, P. T. W., Oldani, G., Segedi, M., Ma, R. M. K., Ho, S. G. F., Dunne, E. M., & Bleszynski, M. S. (2026). Stereotactic body radiation therapy and radioembolization as bridging strategies to liver transplantation: a retrospective real-world analysis. Transplant International, 39, Article 17047. https://doi.org/10.3389/ti.2026.17047

Image Credits: AI Generated

DOI: 10.3389/ti.2026.17047

Keywords: hepatocellular carcinoma, liver transplantation, SBRT, radioembolization, yttrium-90, bridging therapy, radiographic-pathologic discordance, LI-RADS, MELD score, alpha-fetoprotein, locoregional therapy, radiation oncology

The research, led by Jan-Michel Heger of University Hospital Cologne together with colleagues from centers across Germany and Austria, set out to validate which variables are clinically relevant prognostic factors and which act as treatment-effect modifiers in DLBCL. The distinction is technically crucial. A prognostic factor predicts how patients fare overall regardless of which therapy they receive, such as advanced age or high tumor burden. A treatment-effect modifier, by contrast, changes how well a specific therapy works, meaning the treatment’s benefit itself differs depending on the patient’s status. Confusing the two can distort indirect treatment comparisons, the family of statistical methods, including matching-adjusted and simulated treatment comparisons, that health technology assessment bodies increasingly rely on when randomized evidence is absent. If an effect modifier is left unadjusted, the comparison may attribute differences in outcome to the drug when they actually stem from the patient mix.

To build the variable list, the team first drew on a prior systematic literature review of prognostic factors for efficacy and safety outcomes of CAR-T therapy in DLBCL, then refined the candidates through clinical review. Six experienced hematologists and oncologists from Germany and Austria, institutions spanning Cologne, Berlin, Essen, and Vienna, then participated in a structured, two-round expert elicitation process modeled on consensus methodologies such as the Delphi approach. Each expert rated the importance of every candidate variable as a prognostic factor, a treatment-effect modifier, or both, using a three-point Likert scale. Variables that crossed predefined consensus thresholds were assigned to relevance tiers and then mapped to specific clinical endpoints: progression-free survival, overall survival, response outcomes, and CAR-T-related toxicities such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, the two signature adverse events of this therapeutic class.

The findings on prognostic factors were remarkably coherent. Thirteen variables reached the top relevance tier: Eastern Cooperative Oncology Group performance status, age, disease histology, the International Prognostic Index, disease stage, elevated lactate dehydrogenase, bulky disease, extranodal involvement, tumor burden, primary refractory disease, number of relapses, time to relapse, and the number of prior lines of therapy. Six of these achieved unanimous agreement among all panelists as prognostic factors for survival outcomes: ECOG performance status, the IPI, disease histology, disease stage, elevated LDH, and primary refractory disease. These are, for the most part, the venerable workhorses of lymphoma prognostication. The IPI, developed in the early 1990s, combines age, performance status, stage, LDH, and extranodal sites into a single risk score, and its components dominated the panel’s top tier, suggesting that decades of clinical experience have produced a stable, shared understanding of what drives outcomes in aggressive B-cell malignancy.

The logic behind each variable is biologically plausible. ECOG performance status captures a patient’s functional fitness, which influences both tolerance of intensive lymphodepleting chemotherapy before CAR-T infusion and the ability to survive complications. Elevated LDH signals high tumor turnover and burden. Primary refractory disease, meaning lymphoma that never responded to initial therapy, and short time to relapse both mark biologically aggressive, treatment-resistant clones. Number of prior therapy lines reflects cumulative exposure to cytotoxic regimens and often correlates with diminishing responsiveness. Bulky disease and high tumor burden strain not only efficacy but also safety, a point the panel emphasized: tumor burden-related variables were judged important for both efficacy endpoints and toxicity outcomes, including the risk of cytokine release syndrome, in which engineered T cells trigger a systemic inflammatory cascade, and neurotoxicity, which can range from mild confusion to life-threatening cerebral edema.

Where consensus weakened was precisely where the science is least mature: treatment-effect modifiers. Compared with the strong agreement on prognostic factors, substantially lower agreement emerged for effect modifiers, particularly for response-based outcomes such as complete response and overall response rates. Only a handful of variables reached the top tier as effect modifiers: primary refractory disease, time to first relapse, best response to prior therapy, bridging therapy, CAR-T product type, and CAR-T-related response characteristics. Bridging therapy, the treatment given between leukapheresis, when a patient’s T cells are harvested for engineering, and infusion of the final CAR-T product, was the sole modifier to achieve unanimous agreement for complete and overall response rates. That makes intuitive sense: bridging therapy both controls disease during the manufacturing window and may itself select for or against certain patient profiles, entangling its effect with the therapy being evaluated.

The asymmetry between prognostic factors and effect modifiers is not a failure of the panel but a reflection of the evidence base. Identifying a prognostic factor requires only observing that outcomes vary with a characteristic; identifying an effect modifier requires evidence that the magnitude of a treatment’s benefit differs across levels of that characteristic, which demands comparative data that are often simply unavailable. Recent real-world analyses comparing tisagenlecleucel and axicabtagene ciloleucel, the two most widely used CD19-directed CAR-T products in DLBCL, have begun to probe such interactions, but the literature remains thin and heterogeneous. The panel’s hesitancy, in other words, encodes genuine scientific uncertainty rather than disagreement about method. For analysts constructing indirect comparisons, this means adjustment strategies for effect modification must be justified case by case, with sensitivity analyses exploring how conclusions change under different assumptions.

The study’s methodology also carries lessons for the broader field of comparative effectiveness research. Structured expert elicitation has become an accepted tool when empirical data cannot settle a question, and the two-round design with predefined consensus thresholds guards against the dominance of a single loud voice. The approach mirrors frameworks developed by health technology assessment bodies, including the German Institute for Quality and Efficiency in Health Care, which has promoted systematic confounder identification in indirect comparisons. By allocating variables to specific endpoints rather than treating confounding as a generic problem, the panel acknowledged a technical subtlety: a variable may be essential to adjust for when comparing progression-free survival but irrelevant for response rates, and a variable that predicts toxicity, such as tumor burden’s link to cytokine release syndrome, may need separate consideration in safety analyses.

There are caveats worth noting. The panel comprised six clinicians from two neighboring countries with broadly similar treatment landscapes, and their judgments, however experienced, are ultimately structured opinion rather than empirical proof. The study was funded by Miltenyi Biomedicine, a manufacturer of CAR-T technology, with several authors employed by the company or a contract research organization, although the funder reported no role in study design, data collection, or interpretation. Participants were compensated, and the elicitation captured physician judgment rather than patient-level data. These limitations do not undermine the central contribution, but they mean the resulting variable list should be treated as a validated starting framework, to be updated as real-world registries and comparative studies accumulate.

For patients with relapsed or refractory DLBCL, the practical stakes are considerable. CAR-T therapy has transformed outcomes for a population that once had few options, but the therapy is expensive, logistically demanding, and carries real risks, so payers and clinicians need trustworthy evidence about which product or sequence works best for whom. Indirect comparisons are often the only bridge across the gaps in randomized evidence, and this study supplies the engineering specifications for that bridge: a consensus-backed set of prognostic factors that must be balanced, a shorter and more tentative list of effect modifiers demanding caution, and an explicit mapping of variables to endpoints. The next step, the authors and the field suggest, is to test these expert-identified variables empirically in large, multinational real-world datasets, turning structured clinical intuition into statistically verified adjustment models that can withstand regulatory scrutiny.

Subject of Research: Confounder and effect-modifier identification for indirect treatment comparisons of CAR-T therapy in relapsed or refractory diffuse large B-cell lymphoma

Article Title: Confounder Identification in Diffuse Large B-Cell Lymphoma: Findings from an Expert Panel of German and Austrian Hematologists

Article References: Heger, J.-M., Gödel, P., Habringer, S., Jäger, U., Kutsch, N., von Tresckow, B., Zhang, R., Rungaldier, S., Oddsdottir, J., Zacharioudaki, M., & Mahlich, J. (2026). Confounder Identification in Diffuse Large B-Cell Lymphoma: Findings from an Expert Panel of German and Austrian Hematologists. Advances in Therapy. https://doi.org/10.1007/s12325-026-03820-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03820-z

Keywords: diffuse large B-cell lymphoma, CAR-T therapy, confounders, prognostic factors, treatment-effect modifiers, indirect treatment comparisons, expert consensus, bridging therapy, cytokine release syndrome, International Prognostic Index, health technology assessment, hematology

CAR T-cell therapy has reshaped the treatment landscape for relapsed and refractory multiple myeloma. The approach involves collecting a patient’s own T-lymphocytes, engineering them in the laboratory to express a chimeric antigen receptor that recognizes a specific target on cancer cells, expanding the modified cells to large numbers, and reinfusing them into the patient. In myeloma, the preferred target is B cell maturation antigen, or BCMA, a protein abundantly expressed on malignant plasma cells. Two such products, idecabtagene vicleucel and ciltacabtagene autoleucel, have demonstrated high initial response rates in clinical trials and are now established options for patients whose disease has exhausted conventional therapies.

Despite those impressive early results, a major clinical challenge looms: relapse. Most patients who respond to BCMA-directed CAR T-cell therapy eventually experience disease progression, and once that happens, therapeutic options become scarce and prognosis is often poor. Whether a second BCMA-directed CAR T-cell infusion can work after the first one has failed has remained an open question, complicated by concerns that the tumor may have evolved mechanisms of immune escape, including loss or downregulation of the BCMA target itself.

The newly reported case offers a carefully documented data point. The patient had high-risk IgA kappa multiple myeloma and had undergone extensive prior treatment. Idecabtagene vicleucel was administered as his sixth line of therapy, and it produced a deep response lasting approximately one year. When his disease subsequently progressed, the clinical team faced the dilemma of how to bridge him to a potential second cellular therapy while keeping the myeloma under control. Notably, whole genome sequencing performed earlier had confirmed that his myeloma cells still expressed BCMA, providing a molecular rationale for retargeting the same antigen with a different CAR construct.

As bridging therapy, the patient received a combination of mezigdomide, carfilzomib, and dexamethasone. Mezigdomide belongs to the CELMoD class, a new generation of molecular glue degraders that bind cereblon and induce the degradation of proteins central to myeloma cell survival, including Ikaros and Aiolos. This combination rapidly reduced disease burden and allowed the team to proceed with a second BCMA-directed CAR T-cell infusion, this time using ciltacabtagene autoleucel, a product distinguished by a multi-targeting CAR design intended to enhance antigen recognition and reduce tumor escape.

Early post-infusion assessment showed a swift and profound response. Marked declines in serum IgA and free kappa light chains, key myeloma biomarkers, were observed, accompanied by robust expansion of the infused CAR T-cells in the patient’s circulation. The rapidity and depth of the response are particularly notable given the extensive prior treatment and the fact that the patient had already received one BCMA-directed product. The case demonstrates that preserved BCMA expression, confirmed molecularly before retreatment, may help identify patients likely to respond to a second BCMA-targeted cellular therapy.

treatment-related toxicities were described as manageable. The patient experienced grade II cytokine release syndrome, a common inflammatory side effect of CAR T-cell therapy mediated by immune signaling molecules released during T-cell activation, as well as prolonged cytopenias, a reduction in blood cell counts that persisted beyond the expected window. Importantly, there was no evidence of neurotoxicity, another recognized risk of CAR T-cell therapy. These findings reinforce the notion that carefully monitored retreatment can be delivered with an acceptable safety profile even in a heavily pretreated patient.

The authors emphasize that this single case provides additional knowledge rather than definitive proof. It suggests that retreatment with BCMA-directed CAR T-cell therapy may be feasible and clinically effective in heavily pretreated multiple myeloma, particularly in patients who achieved a durable response to their initial CAR T-cell infusion. The combination of bridging therapy to reduce tumor burden and the use of an alternative CAR T-cell construct may further improve outcomes by minimizing disease progression during manufacturing and by presenting the tumor with a different engineered receptor.

The report also highlights the growing role of genomic characterization in treatment planning. In this case, prior whole genome sequencing confirmed preserved BCMA expression, giving clinicians the confidence to pursue a second BCMA-directed approach rather than switching to an alternative target. As sequencing becomes more widely available, such molecular assessments may become a standard part of the decision-making process for patients considering CAR T-cell re-treatment.

Prospective studies will be needed to define optimal patient selection and treatment sequencing in this setting, the authors conclude. Key questions include which patients are most likely to benefit from a second BCMA-directed infusion, the ideal choice and duration of bridging therapy, and whether alternative CAR constructs truly outperform reinfusion of the original product. For now, this case adds to a small but growing body of evidence that a second CAR T-cell chance may be possible for some patients with advanced multiple myeloma.

Subject of Research: Retreatment with BCMA-directed CAR T-cell therapy after CELMoD-based bridging in relapsed multiple myeloma

Article Title: Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma

Article References: Niklas, H., Bold, A., Völkl, S., Lang, N., Truger, M., Wendelin, K., Strifler, S., Gärtner, J., & Knop, S. (2026). Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma. Annals of Hematology. https://doi.org/10.1007/s00277-026-07278-5

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07278-5

Keywords: multiple myeloma, CAR T-cell therapy, BCMA, ciltacabtagene autoleucel, idecabtagene vicleucel, mezigdomide, CELMoD, bridging therapy, relapsed refractory myeloma, cytokine release syndrome, immunotherapy, cell therapy

Mechanical thrombectomy, in which physicians thread catheters through blood vessels to physically remove a clot, is the established standard of care for acute ischemic stroke caused by a large vessel occlusion. Intravenous thrombolysis with the drug alteplase is recommended as first-line therapy within four and a half hours of symptom onset, and beyond that window when perfusion imaging shows salvageable brain tissue. When both treatments are used, the combination is known as bridging therapy. Yet the practice remains debated, because intravenous thrombolysis carries a risk of hemorrhage, and well-designed trials comparing direct thrombectomy with bridging therapy have produced mixed results. A recent Cochrane systematic review pooling six randomized controlled trials found no evidence of a difference in functional outcome, mortality, or intracranial hemorrhage between the two strategies, and its authors called for research into time- and person-specific factors that might determine who benefits from the intravenous drug.

Researchers at University Hospital Carl Gustav Carus in Dresden suspected that one such factor might be the biological composition of the clot itself. Clots removed from patients with large vessel occlusion vary considerably in their proportions of fibrin and red blood cells, and these differences fall largely along etiological lines. Clots of cardiac origin, which form when the heart’s rhythm falters and debris travels to the brain, tend to be rich in fibrin and platelets. Clots arising from atherosclerotic disease in the neck or brain arteries tend to be red blood cell rich. Fibrin-rich clots are denser, create more friction against vessel walls, and are known to be less sensitive to thrombolytic drugs, which work by infiltrating the clot and thinning its fibrin fibers. Red blood cell rich clots, with their more loosely packed fibrin networks, allow greater drug penetration and dissolve more readily.

To test whether these biological differences translate into different treatment outcomes, the team conducted a post hoc analysis of their prospective registry of consecutive thrombectomy patients treated between January 2017 and January 2023. The cohort included 798 adults who underwent thrombectomy for anterior circulation large vessel occlusion, either at the Dresden center directly or after transfer from one of thirteen telestroke network spokes or eight partner primary stroke centers in eastern Saxony. Just over half the patients were women, the median age was 77 years, and the median baseline stroke severity on the National Institutes of Health Stroke Scale was 15. Nearly half of the patients, 395 in total, received intravenous alteplase before thrombectomy; no other thrombolytic agents were used during the study period. Stroke etiology was classified according to the TOAST criteria by senior stroke consultants and validated through a secondary central review of all medical records.

The primary outcome was the time from groin puncture to successful angiographic reperfusion, quantified using the modified Thrombolysis in Cerebral Infarction score, with successful reperfusion defined as a score of 2b or higher. The researchers used stratified Cox proportional hazards regression, adjusting for age, baseline stroke severity, tandem occlusions, carotid T occlusions, occlusion site, and distal thrombus migration—a shift of the clot from a proximal to a more distal arterial segment that occurred before any endovascular maneuver. Overall, successful reperfusion was achieved in 85.2 percent of patients, and cardioembolic stroke accounted for 58.9 percent of cases.

The results split cleanly along etiological lines. Among the 330 patients with non-cardioembolic stroke, bridging intravenous thrombolysis was independently associated with a roughly 40 percent higher hazard of achieving successful reperfusion at any point during the procedure, with an adjusted hazard ratio of 1.40. This effect grew stronger in sensitivity analyses: when patients with stroke of undetermined etiology were excluded, the adjusted hazard ratio rose to 2.06, and a sub-analysis restricted to patients with large artery atherosclerotic stroke reproduced the benefit. Consistent with this, patients with atherosclerotic stroke who received the intravenous drug required about 36 percent fewer aspiration attempts during thrombectomy, an effect measured with a negative binomial regression that accounted for age, initial CT severity score, and occlusion site.

Among the 468 patients with cardioembolic stroke, however, the picture was entirely different. Intravenous thrombolysis alone showed no measurable effect on time to reperfusion, with an adjusted hazard ratio of 1.13 that did not reach statistical significance. More troubling, when the clot migrated distally after thrombolysis and before the procedure—a phenomenon observed in 9.7 percent of cardioembolic patients who received the drug versus 0.8 percent of those who did not—the likelihood of successful reperfusion at any given time point dropped by approximately 43 percent, with an adjusted hazard ratio of 0.57. The researchers propose that when thrombolysis fails to soften a fibrin-rich cardiac clot, it may instead promote its displacement into smaller, more distal arterial segments where thrombectomy is technically harder and less effective, a concern underscored by two recent negative randomized trials of thrombectomy for distal vessel occlusions.

The study also quantified the clinical stakes of procedural speed. Each additional 10 minutes of groin-to-recanalization time increased the odds of a worse functional outcome on the modified Rankin scale at 90 days by 8.6 percent, an association that remained robust after adjustment for patient characteristics, stroke features, interventional parameters, and metabolic markers. In other words, a treatment that accelerates reperfusion in one stroke subtype and delays it in another could meaningfully shift outcomes for individual patients, even if population-level averages obscure the difference.

The mechanistic story fits a growing body of evidence. Analyses of the MR CLEAN Registry biobank and other prospective thrombus studies have shown that cardioembolic clots contain a higher proportion of fibrin and platelets, while atherosclerotic clots are predominantly red blood cell rich. Fibrin-rich thrombi demand more recanalization attempts and yield lower reperfusion rates, and laboratory work suggests they are less susceptible to thrombolytic agents because their fibrin is densely packed. The multicenter RESTORE Registry found that clots retrieved in earlier thrombectomy passes had higher red blood cell content, while later passes yielded fibrin-rich material. Beyond simple histology, molecular analyses have identified neutrophil extracellular traps as structural components that stabilize the fibrin network and may contribute to thrombolysis resistance—raising the possibility that partial clot destabilization without effective lysis could promote distal embolization and increase procedural complexity.

The Dresden team is careful to note the limitations of their work. The data come from a regional network registry, histological characterization of retrieved clots was not available, and the subgroup of cardioembolic patients with distal thrombus migration was small, leaving room for residual confounding despite robust statistical adjustment. Cryptogenic stroke, moreover, is a highly heterogeneous category that may mask diverse underlying mechanisms. Still, the consistency of the etiological differences across all multivariable models, and their reproduction in the atherosclerotic sub-analysis, suggest a robust finding. If confirmed in larger studies, the results could help clinicians move beyond a one-size-fits-all approach to bridging therapy, reserving intravenous thrombolysis for the patients whose clots are most likely to yield to it—and sparing others a treatment that may do more harm than good.

Subject of Research: Effect of intravenous thrombolysis before thrombectomy on reperfusion outcomes in cardioembolic versus non-cardioembolic acute ischemic stroke

Article Title: IV Thrombolysis Facilitates Interventional Reperfusion in Non‐Cardioembolic but Not Cardioembolic Stroke

Article References: Sedghi, A., Kaiser, D. P. O., Arndt, M., Diel, N. J., Simon, E., Polanski, W. H., Puetz, V., Huttner, H. B., & Siepmann, T. (2026). IV Thrombolysis Facilitates Interventional Reperfusion in Non‐Cardioembolic but Not Cardioembolic Stroke. Annals of Clinical and Translational Neurology, 13(9), 1893-1902. https://doi.org/10.1002/acn3.70370

Image Credits: AI Generated

DOI: 10.1002/acn3.70370

Keywords: stroke, thrombectomy, intravenous thrombolysis, large vessel occlusion, cardioembolic stroke, clot composition, reperfusion, alteplase, TOAST classification, distal thrombus migration, fibrin-rich thrombi, bridging therapy